-
Innovation Ranking
NewInnovation Ranking – ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc (ANI) is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals. The company offers pharmaceuticals for central nervous system (CNS) disorders, gastrointestinal, cancer, ophthalmic, metabolic and other diseases. ANI also conducts business as a Contract Development and Manufacturing Organization (CDMO) supporting late-stage development to commercial manufacture of pharmaceutical products including coated/non-coated tablets and capsules, ointments, creams, non-sterile liquids, suspensions, and gels. It markets oncology products, complex formulations, hormones and steroids and controlled...
-
Company Insights
Innovation and Patenting activity of ANI Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ANI Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
NewEnterprise Security Software Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Artificial intelligence (AI) is a double-edged sword in cybersecurity. It can help organizations improve their threat detection, hunting, and incident response capabilities, but adversaries can and will use AI in cyberattacks. There is every likelihood that AI will spur new merger and acquisition (M&A) deals in cybersecurity, especially of companies judged to be AI specialists. In the thematic screen of GlobalData’s enterprise security software sector scorecard, AI has a weighting of 20%, higher than any other theme.
-
Product Insights
NewLikelihood of Approval Analysis for Poisoning
Overview How likely is it that the drugs in Poisoning will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Poisoning Overview A poison refers to any substance harmful to the body, whether...
-
Product Insights
NewLikelihood of Approval Analysis for Swine Influenza
Overview How likely is it that the drugs in Swine Influenza will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Swine Influenza Overview Swine influenza is an infection caused by any of...
-
Product Insights
NewLikelihood of Approval Analysis for Mesenchymal Tumor
Overview How likely is it that the drugs in Mesenchymal Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesenchymal Tumor Overview Mesenchymal tumors are tumors developing from mesenchymal tissues. These...
-
Product Insights
NewLikelihood of Approval Analysis for Papillary Thyroid Cancer
Overview How likely is it that the drugs in Papillary Thyroid Cancer will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Papillary Thyroid Cancer Overview Papillary thyroid cancer (PTC) is the most...
-
Thematic Analysis
NewGlobal M&A Deals in Q1 2024 – Top Themes by Sector – Thematic intelligence
The global M&A market in Q1 2024 witnessed deals worth $613 billion, a rise of 38% compared to Q1 2024. In terms of deal volume, there was a 13% fall from 8,468 deals in Q1 2023 to 7,248 M&A deals in Q1 2024. The TMT sector led the M&A deal activity, with 2,163 deals worth $186 billion recorded in Q1 2024. Most sectors saw a year-on-year increase in deal activity in Q1 2024. Mega-deals (defined as any deal valued at...
-
Sector Analysis
NewGeneral Hospital Supplies Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
General Hospital Supplies Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033 is built to visualize quantitative market trends within Hospital Supplies therapeutic area. The model discusses the effect of COVID -19 on the General Hospital Supplies Market for the year 2020 and beyond. General Hospital Supplies form the equipment base of all healthcare facilities in any country. For any kind of treatment to be successful, it is a necessity that the hospital is equipped with...
-
Product Insights
NewLikelihood of Approval Analysis for Myasthenia Gravis
Overview How likely is it that the drugs in Myasthenia Gravis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Myasthenia Gravis Overview Myasthenia gravis is an autoimmune neuromuscular disease characterized by...